Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL

CONCLUSIONS: Our findings suggest that both pretreatment and D30 MTV are predictive of outcomes among R/R B-NHL patients treated with CAR T-cell therapy. These data indicate that efforts to reduce pretreatment tumor burden may improve longitudinal clinical outcomes. Furthermore, D30 postinfusion MTV quantification may aid clinicians in optimally identifying patients at high-risk for progression, and in whom closer disease monitoring should be considered. MTV also adds prognostic value to patients with high-risk IPI and holds promise for incorporation in novel risk scoring systems which can identify patients prior to CAR T-cell therapy at highest risk of adverse outcomes.PMID:37827881 | DOI:10.1016/j.clml.2023.09.005

Source: Clinical Lymphoma and Myeloma - October 12, 2023 Category: Cancer & Oncology Authors: Alexandra E Rojek Justin P Kline Nicholas Feinberg Daniel E Appelbaum Yonglin Pu Benjamin A Derman Andrzej Jakubowiak Satyajit Kosuri Hongtao Liu Mariam T Nawas Sonali M Smith Michael R Bishop Peter A Riedell Source Type: research